Printer Friendly

Slovakia : Zuzana Simekova and Jean-Marc Grosperrin to co-head Dentons Life Sciences group across Europe.

Dentons, the worlds largest law firm, has appointed Bratislava-based partner Zuzana Simekova as Co-head of the Europe Life Sciences group for the term 2019-2021. She joins Paris-based partner Jean-Marc Grosperrin, who has successfully led the Europe Life Sciences group since its inception in 2014 and who has been reappointed as Co-head for a new term.

Jean-Marc Grosperrin commented, Our Europe Life Sciences group has traditionally been built on the strength of our market-leading practice in Paris which has been expanded throughout Europe. As we look to the future, we plan to start a new phase aimed at further strengthening our capabilities across Europe. So I am very pleased to welcome Zuzana, a leading Life Sciences lawyer in the CEE region, to the leadership team. Zuzana imekov commented, I feel honored to be appointed to this role. Our Europe Life Sciences practice has a very strong standing and I am very much looking forward to enhancing, alongside Jean-Marc and our colleagues, our offering of excellent, full-service support to the clients in this dynamic sector.

Zuzana imekov has been practicing law for more than 15 years and focuses primarily on life sciences and competition law. She advises clients in the pharmaceutical sector in CEE and Europe on a wide range of regulatory issues, including clinical trials, market access, pricing and reimbursement, compliance, distribution and sales models, and advertising. She also has extensive experience in providing regulatory advice and obtaining competition clearance of M&A and corporate transactions in the life sciences sector. She is ranked among the top competition and antitrust lawyers in Slovakia in Chambers Europe 2018. Before joining Dentons, she co-led the European Life Sciences regulatory group at Allen & Overy in Paris. She has worked for clients such as GE Healthcare, Roche and Eli Lilly, and recently she advised Sanofi across numerous European countries in relation to the sale of its generic business division in Europe, one of the largest transactions in the life sciences sector in recent years with transaction amount 1,9 million EUR.

In addition to co-heading the Europe Life Sciences group, Jean-Marc Grosperrin co-heads the top tier Life Sciences group in Paris. He is primarily involved in French and cross-border acquisitions, divestments and private equity transactions, with a focus on the healthcare sector. He recently led the cross-border team advising Lactalis on the 740m acquisition of Aspen Pharmacares infant nutrition business across 20 countries. This was one of the most important global life sciences deals in 2018. He also regularly advises Pfizer in France on all its significant operations as well as other major international pharmaceutical, cosmetics, medical devices, and biotechnology companies. He is ranked among the top lawyers in Pharmaceuticals and Life Sciences M&A in France by Chambers Europe, The Legal 500 EMEA and Best Lawyers.

Tomasz D?browski, CEO of Dentons Europe, commented, As part of our strategy for Europe, we are committed to enhancing our capabilities in key practices and sectors. Under the capable leadership of Jean-Marc and Zuzana, we will enhance our offering of innovative services and add even more value to our clients in the life sciences sector. Dentons Life Sciences sector group includes approximately 425 lawyers worldwide, including 145 lawyers in Europe.

[c] 2019 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
COPYRIGHT 2019 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:4EUFR
Date:Mar 11, 2019
Words:546
Previous Article:Australia : Olympic gold medallists rally to help next generation.
Next Article:Australia : Morphine Sulfate Injection BP 30 mg in 1 mL ampoule.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters